This prospective, open-label, randomised superiority trial was done at 19

hospitals in the UK. We enrolled adults aged at least 18 years presenting to

hospitals with clinically diagnosed, highly probable or confirmed COVID-19
infection, with fewer than 14 days of symptoms, who were considered suitable
for initial ambulatory management. Patients were randomly assigned (1:1) to
azithromycin (500 mg once daily orally for 14 days) plus standard care or to
standard care alone. The primary outcome was death or hospital admission
from any cause over the 28